NuScale Power Plunges 80% to $10: Contrarian Opportunity in Nuclear Renaissance

NuScale Power ($SMR) has seen its stock price crater 80% from its October peak of $53.43 to just $10, triggering a sell-off that may have created a compelling entry point for patient investors betting on the future of nuclear energy. While the precipitous decline reflects near-term uncertainty and extended timelines for commercialization, forward-looking analysts argue the markdown ignores a transformative opportunity in small modular reactor (SMR) technology—a sector poised to reshape global energy infrastructure over the next decade.

The market's pessimism centers on the reality that NuScale won't deploy its first commercial SMRs until the early 2030s, a sobering timeline for investors seeking near-term catalysts. Yet beneath this extended runway lies a compelling growth narrative that could reward contrarian investors willing to tolerate volatility and execution risk.

The Numbers: From Pilot to Profitability

NuScale's financial trajectory tells a story of explosive growth once commercialization begins:

• 2025 Projected Revenue: $31 million (largely development and engineering work)
• 2028 Projected Revenue: $331 million (670% increase in just three years)
• Market Opportunity: Global SMR market projected to reach $5.2 billion by 2035

These projections reflect a company transitioning from the R&D phase to mass production. If NuScale maintains its first-mover advantage in SMR deployment—a critical assumption—the company could potentially generate billions in annual revenue by the mid-to-late 2030s as utilities and industrial customers embrace smaller, more flexible nuclear reactors.

The revenue acceleration from $31 million to $331 million between 2025 and 2028 demonstrates why patient capital might find value at current levels. This represents the inflection point where pilot programs mature into commercial scale, though the company must successfully navigate numerous regulatory, technical, and supply chain hurdles to realize these projections.

Market Context: The SMR Moment

The small modular reactor sector sits at an inflection point driven by converging forces:

Regulatory Tailwinds: Governments worldwide are embracing nuclear energy as carbon-free baseload power, particularly as climate commitments intensify. The U.S., UK, Canada, and Japan have all signaled support for SMR deployment, creating a favorable policy backdrop.

Energy Security: Post-pandemic supply chain disruptions and geopolitical tensions have reinforced the case for domestic, distributed power generation. SMRs offer scalability without the massive capital requirements of traditional gigawatt-scale plants.

Industrial Demand: Beyond electricity generation, SMRs can provide process heat for hydrogen production, desalination, and industrial manufacturing—markets where traditional nuclear plays cannot compete.

First-Mover Advantage: NuScale has secured development contracts with the U.S. Department of Energy and appears positioned as the Western world's leading SMR developer. However, competitors including X-energy, Oklo, and international players in Canada and the UK are advancing competing designs, eroding any monopoly assumptions.

The broader nuclear sector has experienced a renaissance as climate concerns override historical opposition. Traditional nuclear utilities like Constellation Energy ($CEG) and NextEra Energy ($NEE) have renewed focus on reactor development, while a new wave of specialized nuclear companies—$SMR, $OKLO, and others—have captured investor imagination with visions of distributed, safer reactors.

Investor Implications: Risk-Reward Calculus

The 80% decline creates a classic contrarian scenario with substantial caveats:

The Bull Case: Investors who believe NuScale will successfully deploy commercial SMRs by 2033-2034 and capture meaningful market share face a potentially multi-bagger opportunity. If the company achieves even 20-30% of the $5.2 billion global market by 2035 while maintaining operational margins approaching 30-40% (achievable for scaled manufacturing), stockholders could see 10x+ returns from current levels. The long-term energy transition story remains intact regardless of near-term volatility.

The Bear Case: Construction delays, regulatory setbacks, cost overruns, or technical failures could push commercial deployment into the late 2030s or beyond, extending the burn-rate period and increasing dilution risk. Competition from traditional nuclear, renewable energy, and rival SMR developers could compress NuScale's addressable market. The company must execute flawlessly in an industry notorious for complexity and cost control challenges.

The Realistic Middle Ground: NuScale likely represents a legitimate long-term position but unsuitable for risk-averse investors or those requiring near-term returns. The stock's crash reflects legitimate concerns about timelines and execution—not the disappearance of the underlying opportunity. Current valuations appear to price in significant failure scenarios, potentially offering asymmetric risk-reward for investors with 5-10 year horizons.

Capital Requirements: Notably, NuScale's path to profitability requires substantial additional capital raises. Each facility deployment likely necessitates hundreds of millions in financing, creating both opportunity for strategic investors and dilution risk for current shareholders.

The Forward Outlook

NuScale Power's 80% decline reflects market frustration with extended timelines and execution risk—not a broken fundamental thesis. The global energy transition remains inexorable, and SMRs represent a legitimate solution to decarbonization challenges where traditional nuclear cannot compete. The $5.2 billion market by 2035 projection assumes meaningful adoption, and NuScale's first-mover status provides tangible advantages, though hardly guarantees.

For long-term investors, the question isn't whether SMR technology matters—it likely will—but whether NuScale specifically will execute successfully and retain market leadership through a critical decade of commercialization. The stock's depressed valuation reflects legitimate risks; it also potentially reflects overcorrection by a market prone to mood swings. Measured exposure to NuScale at $10 may appeal to those confident in both the SMR thesis and the company's execution capability—provided they can tolerate a multi-year wait and accept the possibility of further near-term volatility.